


PRODUCT INFORMATION



INDY

Item No. 23895

CAS Registry No.: 1169755-45-6
Formal Name: 1Z-(3-ethyl-5-hydroxy-2(3H)-benzothiazolylidene)-2-propanone
MF: $C_{12}H_{13}NO_2S$
FW: 235.3
Purity: $\geq 98\%$
UV/Vis.: λ_{max} : 216, 251, 365 nm
Supplied as: A crystalline solid
Storage: $-20^{\circ}C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

INDY is supplied as a crystalline solid. A stock solution may be made by dissolving the INDY in the solvent of choice. INDY is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of INDY in these solvents is approximately 20 mg/ml. INDY is also slightly soluble in ethanol.

INDY is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, INDY should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. INDY has a solubility of approximately 0.05 mg/ml in a 1:20 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

INDY is an ATP-competitive inhibitor of dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A; $K_i = 180$ nM; $IC_{50} = 240$ nM).¹ It is selective for DYRK1A over monoamine oxidase (MAO) A and B at concentrations up to 100 μ M. INDY inhibits DYRK1A phosphorylation of tau in COS-7 cells expressing EGFP-DYRK1A and EGFP-tau in a concentration-dependent manner. It also restores signaling through nuclear factory of activated T cells (NFAT) and NFAT-dependent transcription in HEK293 cells overexpressing DYRK1A. *In vivo*, INDY reverses developmental deformities induced by DYRK1A overexpression in *X. laevis* embryos. INDY also induces proliferation of human and rat β -cells and increases insulin secretion by human islets *in vitro*.²

References

1. Ogawa, Y., Nonaka, Y., Goto, T., *et al.* Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. *Nat. Commun.* **1:86** (2010).
2. Wang, P., Alvarez-Perez, J.C., Felsenfeld, D.P., *et al.* A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. *Nat. Med.* **21(4)**, 383-388 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM